Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS)
Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS): a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Min Lou, PhD, MD
- Phone Number: 13958007213
- Email: lm99@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Recruiting
- Second Affilated Hospital of Zhejiang University, School of Medicine
-
Contact:
- Min Lou, PhD, MD
- Phone Number: 13958007213
- Email: lm99@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged ≥ 40 years
- High risk of stroke (with ≥ 3 of 8 stroke risk factors, including hypertension, dyslipidemia, diabetes, atrial fibrillation or valvular heart disease, smoking history, obvious overweight or obesity, lack of exercise, family history of stroke, or with transient ischemic attack)
- Written informed consent available
- Willingness to complete all assessments and participate in follow-up
- Adequate Visual and auditory acuity to undergo neuropsychological testing
Exclusion Criteria:
- Nuts, berries, olive oil, or fish allergies
- previously diagnosed dementia
- Suspected dementia after clinical assessment by study physician at screening visit
- Previous history of major head trauma and any intracranial surgery
- Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions
- Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement
- Severe loss of vision, hearing, or communicative ability
- Patients presenting a malignant disease with life expectancy < 3 years
- Participation in an ongoing investigational drug study
- Any MRI contraindications
Exit Criteria:
- Not meet the inclusion criteria
- For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator
- Any adverse or serious adverse events during the study period judged by Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Usual diet advice
|
The usual diet advice include recommendations in guidelines, such as reducing salt and fat intake.
|
|
Active Comparator: ORIENT diet intervention
|
The ORIENT diet has the same basic components of the Dietary Approaches to Stop Hypertension (DASH), Mediterranean and MIND diets, but uniquely adjusting some of components according to the evidence derived from Asian prospective cohorts and the Chinese eating habits.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in brain functional network connectivity assessed by resting state functional magnetic resonance imaging (fMRI)
Time Frame: 6 months
|
Primary Outcome
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the Oriental Intervention for Enhanced Neurocognitive Health (ORIENT) diet scale (minimum value = 0, maximum value = 14, and higher scores mean a better outcome)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in brain functional network efficiency assessed by resting state fMRI
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in brain functional network activity intensity assessed by resting state fMRI
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in brain functional network efficiency assessed by resting state fMRI
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in brain functional network activity intensity assessed by resting state fMRI
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in brain functional network efficiency assessed by resting state fMRI
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in brain functional network activity intensity assessed by resting state fMRI
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in brain functional network connectivity assessed by resting state fMRI
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in brain functional network connectivity assessed by resting state fMRI
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Global cognitive function change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Cognitive domain change assessed with Z-score of a modified National Institute of Neurological Disorders and Stroke and Canadian Stroke Network-Canadian Stroke Network (NINDS-CSN) protocol (higher scores mean a better outcome)
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Cognitive function change assessed with Mini-Mental State Examination (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Cognitive function change assessed by Montreal Cognitive Assessment (minimum value = 0, maximum value = 30, and higher scores mean a better outcome)
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in white matter hyperintensity (WMH) assessed on MRI with T2-Fluid-Attenuated-Inversion-Recovery (FLAIR) sequence
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in lacunes assessed on MRI with T2 FLAIR sequence
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in microbleeds assessed on MRI with Susceptibility Weighted Imaging (SWI) sequence sequence
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in white matter hyperintensity (WMH) assessed on MRI with T2 FLAIR sequence
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in lacunes assessed on MRI with T2 FLAIR sequence
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in lacunes assessed on MRI with T2 FLAIR sequence
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in perivascular spaces assessed on MRI with T2 FLAIR sequence
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in microbleeds assessed on MRI with SWI sequence sequence
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in microbleeds assessed on MRI with SWI sequence sequence
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in brain atrophy (width of the sulci greater than 5mm) assessed on MRI
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in cerebral glymphatic function assessed by non-invasive diffusion tensor image analysis along the perivascular space (ALPS-index)
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Changes in cerebral blood flow (CBF) in the territory of the culprit artery assessed by arterial spin labeling (ASL) perfusion image
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Metabolite profiles in participants' faecal samples and serum samples
Time Frame: 6 months
|
short-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)
|
6 months
|
|
Metabolite profiles in participants' faecal samples and serum samples
Time Frame: 2 years
|
long-term secondary outcome: metabolite composition was analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS)
|
2 years
|
|
Incidence of stroke event including ischemic and hemorrhagic stroke
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
|
Incidence of stroke event including ischemic and hemorrhagic stroke
Time Frame: 2 years
|
long-term secondary outcome
|
2 years
|
|
Incidence of stroke event including ischemic and hemorrhagic stroke
Time Frame: 5 years
|
long-term secondary outcome
|
5 years
|
|
Change in the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND) diet scale (minimum value = 0, maximum value = 15, and higher scores mean a better outcome)
Time Frame: 6 months
|
short-term secondary outcome
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ENDS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.